DNLI
DNLI
NASDAQ · Biotechnology

Denali Therapeutics Inc

$24.83
+0.10 (+0.40%)
As of Aug 8, 1:29 AM ET ·
Analyst Consensus
Strong Buy
25
Analysts
High
Coverage
Buy 23 92%
Hold 2 8%
Sell 0 0%
Price Target
Analyst Price Target +208.3% upside
Low Target $56.04
Average Target $76.55
High Target $105.76
Current Price $24.83
Current
$24.83
Target
$76.55
$56.04 $76.55 avg $105.76
Scenario Analysis
Bear Case
$56.04
125.7%
Low target
Base Case
$76.55
+208.3%
Avg target
Bull Case
$105.76
+325.9%
High target
Risk/Reward
2.6x
Favorable
Price in Context
52-Week High
$27.30
-9.0% from high
52-Week Low
$12.58
+97.4% from low
50-Day SMA
$18.67
+33.0% vs SMA
200-Day SMA
$15.96
+55.6% vs SMA
RSI (14)
42.3
Neutral
Target vs 52W High
$76.55
+180.4% vs high
Next Earnings Report
Aug 10, 2026
1d
tomorrow
EPS Est: $-0.68
Earnings in 1 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 79% $257.58 +4.7%
AMGN
Amgen Inc
Hold 43 49% $190.87 -53.6%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +172.3%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 40 83% $438.34 -11.6%
REGN
Regeneron Pharmaceuticals
Buy 38 71% $76.80 -90.2%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -55.6%
RVMD
Revolution Medicines Inc
Strong Buy 29 93% $114.11 -44.4%
BIIB
Biogen Inc
Buy 44 64% $91.45 -56.0%